TriangleAzacitidine (NCT03586609)
Azacitidine trial for Acute Myeloid Leukemia (NCT03586609). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people with untreated AML, generally aged fifty or older. Younger patients unsuitable for standard induction may qualify with investigator approval. Prior venetoclax and acute promyelocytic leukemia are excluded.
The idea: combine venetoclax, cladribine and low-dose cytarabine, then alternate that regimen with azacitidine plus venetoclax. Venetoclax blocks BCL-2 survival signaling; cladribine and cytarabine disrupt DNA; azacitidine changes DNA methylation. Researchers measure remissions, survival and toxicity. Some prior medicines used for stabilization are allowed.
This phase 2 study plans 145 patients. Tapan Kadia leads MD Anderson's single recruiting Houston site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.